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 so the continuous-infusion method
proposed by Drs. Schneemann and Imhof seems
counterintuitive. No clinical trial of continuous infu-
sion has had sufficient power to demonstrate equal
efficacy between continuous infusion and intermit-
tent infusion of amphotericin B deoxycholate.
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Single-Dose Azithromycin for Trachoma
 
to the editor: 
 
Solomon et al. (Nov. 4 issue)
 
1
 
 sug-
gest that the ocular chlamydia that causes trachoma
can be eliminated by a single mass antibiotic treat-
ment. Two years after distributing oral azithromy-
cin in a village, they identified only a single infec-
tion. The authors state that this finding “contrasts
starkly” with the prediction of our mathematical
model.
 
2,3
 
 Yes and no. We do predict that infection
will eventually return after a single mass treatment.
However, with 97.5 percent coverage of a moder-
ately infected area, this return may take a long time.
Our model predicts that less than 3 percent of per-
sons will be infected at one year — and an even
smaller proportion in this case, since Solomon et
al. also distributed tetracycline ointment. Further-
more, this estimate is only an expectation (or aver-
age), and chance can have a large effect. We recently
monitored 24 villages in Ethiopia after a single mass
treatment; in some villages, infection was eliminat-
ed at two months, and in others it returned relative-
ly rapidly.
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 Unfortunately, the evidence so far sug-
gests that, on average, infection returns after a single
mass treatment, but to test this properly, one must
look at more than one village.
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the authors reply: 
 
Two main factors differenti-
ate our study from the model of Lietman et al.
 
1
 
 First,
our primary outcome measure was an adjusted geo-
metric mean of the ocular 
 
Chlamydia trachomatis
 
 load,
determined with the use of a quantitative polymer-
ase-chain-reaction assay. The model, in contrast,
used the prevalence of active trachoma, which cor-
relates poorly with chlamydial infection.
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 Second,
we reported that after high-coverage mass treat-
ment, the load of infection dropped and then con-
tinued to fall for at least two years, whereas the mod-
el predicted that (in communities like ours, where
the disease is mesoendemic) the prevalence of dis-
ease would double every four to eight months after
a treatment-induced fall. Our results suggest that
there may be a threshold level of infection, below
which the transmission of trachoma ceases; its re-
turn might then depend on reintroduction from the
outside by persons with heavy shedding of 
 
C. tra-
chomatis.
 
 We agree that our data are from only a sin-
gle community case study but note that six months
after mass treatment, six Ethiopian villages studied
by Lietman’s group had a prevalence of infection of
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0 percent.
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 Modeling with the use of quantitative
infection data would be a useful next step.
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Controlling Health Care Costs
 
to the editor:  
 
In their recent articles on rising
health care costs, economists Paul Ginsburg (Oct.
14 issue)
 
1
 
 and Joseph Newhouse (Oct. 21 issue)
 
2
 
and presidential candidates John Kerry and George
Bush (Oct. 28 issue)
 
3
 
 do not directly address the
well-known fact that approximately 10 percent of
patients account for 70 percent of costs.
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 To con-
trol costs we must acknowledge this skewed distri-
bution and honestly address the major factor driv-
ing costs: the growth of technology.
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 Managed
care’s lack of candor undermined its efforts to con-
trol costs and led to patient backlash.
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 Since ration-
ing is politically untenable, government has retreat-
ed from these issues. And current efforts at patient
cost-sharing with caps will not curb spending for
those with high utilization.
However, in order to obtain basic health care,
some patients are willing to accept limits on care.
We need efficient insurance systems in which pa-
tients willing to accept such limits are linked with
caring physicians who use innovative practice styles
and consider both costs and benefits as they care
for their patients. Although this approach may
make some uncomfortable, it is both ethical and
necessary.
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to the editor: 
 
Dramatic advances in medicine and
technology have resulted in widespread benefits
from lifesaving but expensive devices and drugs
such as implantable cardiac defibrillators, drug-
eluting coronary stents, and new chemotherapeu-
tic agents. Interestingly, three of the four options
for reducing rising health care costs proposed by
Dr. Ginsburg would require people to obtain less
medical care. If our society continues to reject limi-
tations on health care acquisition, one reality must
be faced by all: whenever technological advances oc-
cur, there are increased costs to individuals (for ex-
ample, automobiles cost more than horses and bug-
gies, televisions cost more than radios, and air
travel costs more than rail travel). Our hope is that,
over time, cost containment can occur as a result of
three mechanisms: reductions in the price of tech-
nologies through free-market competition, medi-
cal-liability reform (which will reduce the practice
of defensive medicine),
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and the growth of informa-
tion technology, leading to a more efficient sys-
tem.
 
2,3
 
 Until then, the American people must as-
sume some personal responsibility for financing
the most advanced health care system in order to
continue to reap its benefits.
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